Overview

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.
Phase:
Phase 2
Details
Lead Sponsor:
Ansun Biopharma, Inc.